Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer.
- Author:
Jing FU
1
;
Jun ZHANG
;
Hong-wei ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Carcinoma, Non-Small-Cell Lung; genetics; pathology; secondary; Cyclin-Dependent Kinase Inhibitor p16; biosynthesis; genetics; DNA Methylation; DNA, Neoplasm; genetics; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p16; Humans; Lung Neoplasms; genetics; pathology; Lymphatic Metastasis; Prognosis; Promoter Regions, Genetic; genetics; RNA, Messenger; biosynthesis; genetics; Survival Rate
- From: Chinese Journal of Pathology 2003;32(2):133-136
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the ways of inactivation and expression of p16 gene mRNA and its protein as well, and their clinicopathological significance in non-small cell lung carcinomas (NSCLC).
METHODSComparative- multiplex PCR, in situ hybridization, and immunohistochemistry were used to detect the promotor methylation status, mRNA, and protein expression in 64 cases of NSCLC, respectively.
RESULTSPromoter methylation of p16 gene was detected in 36 (56.3%) of 64 NSCLC cases. This positive result of methylation showed a negative correlation statistically with p16 protein expression by immunohistochemistry (P < 0.05). By in situ hybridization, 13 cases (20.3%) showed positive results for mRNA and all of these positive cases (13/13) had also a positive result by immunohistochemistry. Thirty-seven cases (57.8%) showed a negative immunohistochemical result. The metastatic rate of lymph nodes of those NSCLC patients with either promoter methylation or negative protein expression was higher (P = 0.038), and 3-year survival rate was lower statistically (P = 0.002).
CONCLUSIONDysfunction of p16 gene in NSCLC is mainly caused by promoter methylation, and patients with p16 gene dysfunction may have a poor prognosis.
